REG - Croda International - Director Declaration

Croda InternationalAnnouncement

09/01/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260109:nRSI2304Oa&default-theme=true

RNS Number : 2304O  Croda International PLC  09 January 2026

9 January 2026

 

Croda International Plc

 

The Board of Croda International Plc is pleased to announce the appointment of
Jill Anderson as a Non-Executive Director. Jill will join the Board on 12
January 2026 and become a member of the Audit, Nomination and Remuneration
Committees.

 

Jill brings more than 30 years' experience in international leadership
positions in the healthcare industry, including executive responsibility in
finance, commercial research and supply chain functions. Most recently, Jill
was Chief Financial Officer of GSK's R&D division until she retired in
2024.

 

Jill is currently a Non-Executive Director and Audit Committee Chair at Spire
Healthcare Group plc.

 

Danuta Gray, Chair of Croda International Plc, commented:

 

"I am delighted to welcome Jill to the Croda Board.  Jill's healthcare sector
experience, combined with her deep financial knowledge and her recent role as
a serving Executive make her an excellent addition to the Board."

 

Jill Anderson commented:

 

"I feel very privileged to be joining Croda, especially given the strong
purpose and commitment to use innovation with Smart science to improve
lives(TM). Croda has an exciting future, and I look forward to working as part
of the Croda team."

 

There are no further matters to be disclosed under LR9.6.13R of the Listing
Rules of the UK Listing Authority.

 

 

For enquiries contact:

 

Investors:        David Bishop,
Croda                           +44 7823 874428

 

Media:             Charlie Armitstead, FTI Consulting     +44
7703 330269

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAKFPEDDKEFA



            Copyright 2019 Regulatory News Service, all rights reserved